401892-47-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-chloro-4-iodopyridine is used as a building block in the synthesis of various biologically active molecules. Its versatile reactivity and unique combination of substituents make it a valuable intermediate in the production of pharmaceuticals.
Used in Agrochemicals:
5-Bromo-2-chloro-4-iodopyridine is also used as an intermediate in the production of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Research and Development:
5-Bromo-2-chloro-4-iodopyridine serves as a reagent in the development of new compounds for research and development purposes. Its unique properties and reactivity make it a promising candidate for exploring novel chemical reactions and syntheses.

InChI:InChI=1/C5H2BrClIN/c6-3-2-9-5(7)1-4(3)8/h1-2H

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 

Downstream Products

• 401892-48-6 5-bromo-2-chloro-4-(2-chloro-phenyl)-pyridine 
• 1801787-56-3 6-oxo-4-trifluoromethyl-1,6-dihydro-pyridine-3-carboxylic acid [4-(4-methyl-piperazin-1-yl)-3'-morpholin-4-ylmethyl-biphenyl-3-yl]-amide 

Relevant academic research and scientific papers

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

2-AMINO SUBSTITUTED PYRIDINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a 2-amino substituted pyridine derivative useful as an active ingredient of medicines such as antipsychotic agent, anti-anxiety agent, or brain function improver. SOLUTION: The present invention provides a compound represe

Logistic flexibility in the preparation of isomeric halopyridinecarboxylic acids

Although there are many conceivable ways to funtionalize, and specifically carboxylate, 2-chloro-4-(trifluoromethyl)pyridine optionally at all three vacant positions, it is more straightforward to prepare only the 2-chloro-4- (trifluoromethyl)pyridine-3-carboxylic acid (1) from this precursor and the other 6-chloro-4-(trifluoromethyl)pyridine-2- and -3-carboxylic acids (2 and 3) from a different one, viz. 5-bromo-2-chloro-4-(trifluoromethyl)pyridine. In the same manner, it proved more convenient to convert 5-chloro-2-(trifluoromethyl) pyridine in only two of the corresponding acids (6 and 7) and to make the third one (8) from 3-bromo-5-chloro-2-(trifluoromethyl)pyridine as an alternative starting material. All model substrates for functionalization were readily accessible from the correspondingly substituted chloroiodopyridine through heavy halogen displacement by in situ generated (trifluoromethyl)copper. Graphical Abstract

Unusual t-BuLi induced ortholithiation versus halogen-lithium exchange in bromopyridines: Two alternative strategies for functionalization

The reaction of lithiating agents with various 3-bromopyridines has been investigated. An unprecedented selectivity was observed with t-BuLi, which effected a clean lithiation at C-4. With 3-bromo and 2-chloro-3-bromo pyridines, the ortholithiation-exchange ratio was strongly electrophile and addition order dependent while 2-chloro-5-bromopyridine always gave exclusive C-4 substitution.

Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors

Substituted 4-phenyl-pyridine compounds with activity as antagonists of Neurokinin 1 receptors, methods of making these compounds and preparing.